| NDC包装代码 | 产品NDC | 产品类型 | 商品名 | 通用名 | 剂型 | 给药途径 | 上市日期 | 结束日期 | 市场类别 | 申请号 | 标签持有者 | 活性成分 | 规格 | 包装描述 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51224-009-20 | 51224-009 | HUMAN PRESCRIPTION DRUG | Cholestyramine Light | Cholestyramine | POWDER, FOR SUSPENSION | ORAL | 20201112 | N/A | ANDA | ANDA209599 | TAGI Pharma, Inc. | CHOLESTYRAMINE | 4 g/4.8g | 60 POUCH in 1 CARTON (51224-009-20) / 4.8 g in 1 POUCH |
| 51224-009-10 | 51224-009 | HUMAN PRESCRIPTION DRUG | Cholestyramine Light | Cholestyramine | POWDER, FOR SUSPENSION | ORAL | 20201112 | N/A | ANDA | ANDA209599 | TAGI Pharma, Inc. | CHOLESTYRAMINE | 4 g/4.8g | 201.6 g in 1 CAN (51224-009-10) |
| 68094-906-20 | 68094-906 | HUMAN PRESCRIPTION DRUG | Cholestyramine | Cholestyramine | POWDER, FOR SUSPENSION | ORAL | 20231215 | N/A | ANDA | ANDA209599 | Precision Dose, Inc. | CHOLESTYRAMINE | 4 g/4.8g | 60 POUCH in 1 CARTON (68094-906-20) / 4.8 g in 1 POUCH |
| 68094-906-10 | 68094-906 | HUMAN PRESCRIPTION DRUG | Cholestyramine | Cholestyramine | POWDER, FOR SUSPENSION | ORAL | 20231215 | N/A | ANDA | ANDA209599 | Precision Dose, Inc. | CHOLESTYRAMINE | 4 g/4.8g | 201.6 g in 1 CAN (68094-906-10) |